Eloxx Pharmaceuticals, Inc.’s (NASDAQ:ELOX) Quiet Period To End on July 20th

Eloxx Pharmaceuticals’ (NASDAQ:ELOX) quiet period will expire on Monday, July 20th. Eloxx Pharmaceuticals had issued 2,975,000 shares in its initial public offering on June 9th. The total size of the offering was $32,725,000 based on an initial share price of $11.00. During Eloxx Pharmaceuticals’ quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Eloxx Pharmaceuticals Stock Performance

Shares of NASDAQ ELOX opened at $11.81 on Monday. The firm has a market capitalization of $8.15 million, a price-to-earnings ratio of -0.77 and a beta of -1,891.27. Eloxx Pharmaceuticals has a 1 year low of $11.00 and a 1 year high of $17.50. The stock’s 50 day moving average price is $17.53.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.